Skip to main content

Table 3 Outcomes between the mPSL alone and rTM groups after the stabilised IPTW

From: Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study

  mPSL alone group rTM group
All patients, (n) 2611 190
 In-hospital mortality, n (%) 1990 (76.2) 149 (78.4)
 14-day mortality, n (%) 746 (28.6) 46 (24.2)
 28-day mortality, n (%) 1382 (52.9) 90 (47.4)
 Bleeding eventsa 73 (2.8) 8 (4.2)
 Length of hospital stay (days), median (IQR) 22 (13–42) 27 (14–42)
Survivor, (n) 622 41
 Bleeding eventsa 12 (1.9) 0 (0)
 Length of hospital stay (days), median (IQR) 41 (24–64) 50 (32–78)
  1. IQR interquartile range, mPSL methylprednisolone, rTM recombinant human soluble thrombomodulin
  2. aBleeding events included epistaxis, hemoptysis, pulmonary hemorrhage, subcutaneous hemorrhage, purpura, muscle hemorrhage, hematuria, gastrointestinal bleeding, bloody stool and intracranial hemorrhage